Memantine as a Supplement to Naltrexone in Treating Heroin Dependence (NAMHS)
Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence
Sponsor: National Institute on Drug Abuse (NIDA)
A PHASE2/PHASE3 clinical study on Heroin Dependence and Opioid Dependence, this trial is completed. The trial is conducted by National Institute on Drug Abuse (NIDA) and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 4 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute on Drug Abuse (NIDA)
- New York State Psychiatric Institute
For direct contact, visit the study record on ClinicalTrials.gov .